Analysts expect Aytu Biopharma, Inc to report revenue of 51.20 M for 2026, against a range of 49.40 M to 53.01 M. The most recent reported year, 2025, came in at 66.38 M, a 10.2% miss against the 73.96 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 65.63 M | 96.67 M | 107.40 M | 81.00 M | 66.38 M | - | - | |
| High Estimate | 69.04 M | 93.48 M | 113.94 M | 83.15 M | 79.14 M | 53.01 M | 72.17 M | |
| Low Estimate | 58.55 M | 86.87 M | 102.38 M | 73.39 M | 68.77 M | 49.40 M | 59.29 M | |
| Consensus Estimate | 63.80 M | 90.17 M | 108.16 M | 78.27 M | 73.96 M | 51.20 M | 65.73 M |
Analysts expect Aytu Biopharma, Inc to report earnings per share of -1.08 for 2026, against a range of -1.17 to -0.99. The most recent reported year, 2025, came in at -2.26, a 745.7% miss against the 0.35 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -69.60 | -75.00 | -5.11 | -2.86 | -2.26 | - | - | |
| High Estimate | -52.25 | -63.32 | -6.09 | -2.12 | 0.37 | -0.99 | -0.08 | |
| Low Estimate | -63.77 | -75.78 | -6.85 | -2.56 | 0.33 | -1.17 | -0.08 | |
| Consensus Estimate | -58.01 | -69.55 | -6.47 | -2.34 | 0.35 | -1.08 | -0.08 |